The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will take place May 29 – June 2 in Chicago, IL. As the world’s largest, most influential, and authoritative oncology conference, ASCO drives global progress in cancer research, clinical development, and patient care.
MediLink Therapeutics, a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), will present multiple high-profile clinical updates across Clinical Science Symposium, Rapid Oral Presentation, and Poster sessions at this year’s meeting, highlighting transformative data from its core oncology pipeline.
Highlighted Presentations
Clinical Science Symposium
Title: Phase 1/2 study of YL201, an anti-B7H3 ADC, in patients with relapsed/refractory Ewing sarcoma and chondrosarcoma
Abstract #: 11510
Presenter: Dr. Lu Xie, Peking University People’s Hospital
Summary: The prognosis for R/R sarcoma remains dismal with limited effective treatment options. YL201 is a B7H3-targeting ADC with promising activity in multiple advanced solid tumors. The safety and preliminary efficacy of YL201 monotherapy in patients with Ewing sarcoma (EWS) and chondrosarcoma (CHS) from a phase 1/2 study is reported.
Rapid Oral Presentation
Title: Phase 2 study of YL201 in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
Abstract #: 5015
Presenter: Dr. Yao Zhu, Fudan University Shanghai Cancer Center
Summary: The treatment of mCRPC remains challenging, especially for patients who progressed on androgen receptor axis-targeted therapy (ARAT) with or without taxane-based chemotherapy.. The safety and preliminary efficacy of YL201 monotherapy in heavily pretreated mCRPC patients from a phase 2 study is reported.
Poster
Title: Phase 1/2 study of YL201 in previously treated advanced pancreatic ductal adenocarcinoma (PDAC)
Abstract #: 4208
Presenter: Dr. Liwei Wang, Renji Hospital, Shanghai Jiao Tong University School of Medicine
Summary: The prognosis for patients with advanced PDAC after failure of first-line therapy remains dismal with limited effective treatment options. There is a critical unmet need for novel therapeutic agents in the second line and beyond (2L+) setting. The safety and preliminary efficacy of YL201 monotherapy in patients with 2L+ PDAC from a phase 1/2 dose expansion study is reported.
Poster
Title: YL205, a novel anti-NaPi2b ADC, in ovarian cancer: preliminary results from a first-in-human trial
Abstract #: 5551
Presenter: Dr. Xiaohua Wu, Fudan University Shanghai Cancer Center
Summary: YL205 (powered by MediLink’s proprietary TMALIN® platform) demonstrates favorable safety and promising anti-tumor activity in ovarian cancer. The trial is enrolling simultaneously in the US and China.
These data reinforce MediLink Therapeutics’ leadership in next-generation ADCs and its commitment to bringing life‑changing therapies to patients worldwide.
#ASCO2026 #ADC #CancerResearch #Oncology #MediLinkTherapeutics #YL201 #YL205 #BiotechInnovation #ChinaBiotech
